b. riley - Search News

B. Riley, Foghorn Therapeutics

Foghorn Therapeutics a new buy at B Riley on tumor fighting technology

B. Riley initiates Foghorn Therapeutics at buy with $10 price target, citing promising development of SMARCA2 inhibitors for tumor treatment. Read more here.

Fintel on MSN · 7h

B. Riley Securities Initiates Coverage of Foghorn Therapeutics (FHTX) with Buy Recommendation

Fintel reports that on January 30, 2025, B. Riley Securities initiated coverage of Foghorn Therapeutics (NasdaqGM:FHTX) with a Buy recommendation. Analyst Price Forecast Suggests 207.54% Upside As of January 28,

Business Insider · 8h

Foghorn Therapeutics initiated with a Buy at B. Riley

B. Riley initiated coverage of Foghorn Therapeutics (FHTX) with a Buy rating and $10 price target. The firm says its investment thesis centers

8don MSN

B. Riley Financial suspends dividends on preferred shares, plans to pay off notes

B. Riley Financial Inc (NASDAQ:RILY). has paused the payment of dividends on two of its preferred stock offerings. The ...

13h

What is B. Riley’s Forecast for CUBI Q1 Earnings?

B. Riley issued their Q1 2025 earnings estimates for Customers Bancorp in a research note issued to investors on Monday, ...

3don MSN

B. Riley upgrades Redwire on growth potential from Edge Autonomy acquisition

Learn about the latest financial trends and strategies in our comprehensive article written by a financial expert.

ClearPoint Neuro price target raised to $20 from $15 at B. Riley

B. Riley analyst Kyle Bauser raised the firm’s price target on ClearPoint Neuro (CLPT) to $20 from $15 and keeps a Buy rating ...

B.Riley Financial Reaffirms Their Buy Rating on Altimmune (ALT)

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Altimmune (ALT – Research Report) yesterday and set a price target of ...

13h

FY2024 EPS Estimates for Ladder Capital Cut by B. Riley

Analysts at B. Riley reduced their FY2024 earnings estimates for shares of Ladder Capital in a research report issued to clients and investors on Monday, January 27th. B. Riley analyst R. Binner now ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results